ืฉืœื™ื—ืช ื™ื•ืžื ื™ื, ื”ืชืจืื•ืช ื•ื ืชื•ื ื™ ื˜ืœืžื˜ืจื™ื” ื‘ืืžืฆืขื•ืช ื“ื™ื•ื“ื” ื ืชื•ื ื™ื

ื’ืœื• ื›ื™ืฆื“
ืื ื• ืžืฉืชืžืฉื™ื ื‘ื‘ื™ื ื” ืžืœืื›ื•ืชื™ืช ืœืชืจื’ื•ื ื”ืืชืจ, ื•ืขืœ ืืฃ ืฉืื ื• ืฉื•ืืคื™ื ืœื“ื™ื•ืง ืžืจื‘ื™, ื™ื™ืชื›ืŸ ืฉื”ืชืจื’ื•ืžื™ื ืื™ื ื ืžื“ื•ื™ืงื™ื ื‘ืžืืช ื”ืื—ื•ื–ื™ื. ืื ื• ืžื•ื“ื™ื ืœืš ืขืœ ื”ื”ื‘ื ื”.

ื”ื’ื ื” ืขืœ ื ืชื•ื ื™ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช ื“ื™ื’ื™ื˜ืœื™ื™ื ืžืคื ื™ ืžืชืงืคื•ืช ืกื™ื™ื‘ืจ

ืขึทืœ ื™ึฐื“ึตื™ ืกื˜ืœื” ื ื’ื•ื™ืŸ, ืžื ื”ืœืช ืฉื™ื•ื•ืง ืžื•ืฆืจ ื‘ื›ื™ืจื”
ืฉืชืฃ ืืช ื”ืคื•ืกื˜ ื”ื–ื”

ื”ืขื™ื“ืŸ ื”ื—ื“ืฉ ืฉืœ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช ื“ื™ื’ื™ื˜ืœื™ื™ื

ื‘ืžื”ืœืš ื”ืฉื ื” ื”ืื—ืจื•ื ื” ื—ืœื” ื”ืชืงื“ืžื•ืช ืžืฉืžืขื•ืชื™ืช ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืช ื”ื“ื™ื’ื™ื˜ืœื™ืช ื•ื”ื˜ื›ื ื•ืœื•ื’ื™ื”, ื›ืืฉืจ ื—ื‘ืจื•ืช ืžืคืชื—ื•ืช ืœืœื ื”ืจืฃ ืคืชืจื•ื ื•ืช ืœืชืžื™ื›ื” ื‘ื—ื•ืœื™ื ื•ื‘ืจื•ืคืื™ื ื›ืื—ื“. ื”ื“ื™ื’ื™ื˜ืฆื™ื” ื•ื”ืื•ื˜ื•ืžืฆื™ื” ื”ืžืชืžืฉื›ื•ืช ืฉืœ ืžืขืจื›ื•ืช ื”ื‘ืจื™ืื•ืช ื˜ื•ืžื ื•ืช ื‘ื—ื•ื‘ืŸ ืคื•ื˜ื ืฆื™ืืœ ืขืฆื•ื ืœืฉื™ืคื•ืจ ืชื•ืฆืื•ืช ื”ื‘ืจื™ืื•ืช. ืขื ื–ืืช, ื›ืคื™ ืฉืจืื™ื ื• ื‘ืžืชืงืคืช ื”ืกื™ื™ื‘ืจ ื”ืžืชื•ืงืฉืจืช ื”ืื—ืจื•ื ื” ื ื’ื“ Change Health, ื”ืชืคืฉื˜ื•ืช ื”ืฉื™ืจื•ืชื™ื ื”ื“ื™ื’ื™ื˜ืœื™ื™ื ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืช ืžืฆื™ื‘ื” ื’ื ืืชื’ืจ ื—ืกืจ ืชืงื“ื™ื ื‘ื”ื’ื ื” ืขืœ ื ืชื•ื ื™ื ืจืคื•ืื™ื™ื.ย 

ืžื ื”ืœื™ IT ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืช ื—ื™ื™ื‘ื™ื ืœื™ื™ืฉื ื‘ืงืจื•ืช ืื‘ื˜ื—ื” ื—ื–ืงื•ืช ื•ืœืงื‘ืœ ื ืจืื•ืช ืœื’ื‘ื™ ื”ืชื ื”ื’ื•ืช ื”ืžืฉืชืžืฉื™ื ื›ื“ื™ ืœื ื˜ืจ ื‘ื™ืขื™ืœื•ืช ืืช ืฉืœืžื•ืช ื”ื ืชื•ื ื™ื. ื“ื‘ืจ ื–ื” ืžื—ื™ื™ื‘ ืื™ืžื•ืฅ ื’ื™ืฉื” ืžืžื•ืงื“ืช ืื“ื ื•ื ื™ื˜ื•ืจ ืชื ื•ืขืช ื ืชื•ื ื™ื ื›ื“ื™ ืœื•ื•ื“ื ื›ื•ื•ื ื” ื•ืœื”ื‘ื˜ื™ื— ื”ื’ื ื” ืขืœ ื”ื ืชื•ื ื™ื. ื‘ืขื•ื“ ืฉื—ื™ื‘ื•ืจ ืžืฉืชืžืฉื™ื ืœื ืชื•ื ื™ื ืจืคื•ืื™ื™ื ืจื’ื™ืฉื™ื ื“ืจืš ืขืจื•ืฆื™ื ืžืื•ื‘ื˜ื—ื™ื ื”ื•ื ืงืจื™ื˜ื™, ื–ื”ื• ืจืง ื”ื™ื‘ื˜ ืื—ื“ ืฉืœ ืžืกื’ืจืช ื”ืื‘ื˜ื—ื” ื”ืจื—ื‘ื” ื™ื•ืชืจ. ื‘ื ื•ืกืฃ, ื›ื›ืœ ืฉืื•ื˜ื•ืžืฆื™ื” ืฉืœ ืชื”ืœื™ื›ื™ ื‘ืจื™ืื•ืช ืžืฉืคืจืช ืืช ื”ื™ืขื™ืœื•ืช ื‘ืงื‘ืœืช ื”ื”ื—ืœื˜ื•ืช, ื”ื™ื ื’ื ืžืฆื™ื’ื” ืกื™ื›ื•ื ื™ื ืœืื•ื‘ื“ืŸ ื ืชื•ื ื™ื. ืื•ื‘ื“ืŸ ื›ื–ื” ื™ื›ื•ืœ ืœื”ืชื‘ื˜ื ื‘ืฆื•ืจื•ืช ืฉื•ื ื•ืช, ื›ื•ืœืœ ื’ื ื™ื‘ืช ืžื™ื“ืข, ื“ืœื™ืคื•ืช ื ืชื•ื ื™ื, ืžื ื™ืคื•ืœืฆื™ื” ื•ืฉื™ืชื•ืฃ ืœื ืžื•ืจืฉื” ืขื ืฆื“ื“ื™ื ืฉืœื™ืฉื™ื™ื. ืœื›ืŸ, ื™ื™ืฉื•ื ืืžืฆืขื™ื ืœืžื ื™ืขืช ืื•ื‘ื“ืŸ ื ืชื•ื ื™ื (DLP) ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืช ื”ื•ื ื—ื™ื•ื ื™.ย 

ืžืชืงืคื•ืช ืกื™ื™ื‘ืจ ืžืชื•ืงืฉืจื•ืช ืขืœ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช

ื‘ืฉื ืช 2023, ื“ื™ื•ื•ื— ืžืฉืจื“ ื–ื›ื•ื™ื•ืช ื”ืื–ืจื— (OCR) ืฉืœ ืžืฉืจื“ ื”ื‘ืจื™ืื•ืช ื•ืฉื™ืจื•ืชื™ ื”ืื ื•ืฉ (HHS) ืขืœ 541 ืžืงืจื™ื ืฉืœ ืคืจืฆื•ืช ื ืชื•ื ื™ื ืฉื”ืฉืคื™ืขื• ืขืœ ืœืžืขืœื” ืž-500 ืื ืฉื™ื . ื—ืœืง ืžื”ืื™ืจื•ืขื™ื ื”ืœืœื• ื”ืฉืคื™ืขื• ืขืœ ืžื™ืœื™ื•ื ื™ื, ืื• ืืคื™ืœื• ืขืฉืจื•ืช ืžื™ืœื™ื•ื ื™ ืื ืฉื™ื, ื›ืžื• ืœืžืฉืœ ื”ืคืจืฆื” ืฉื–ื›ืชื” ืœืคืจืกื•ื ื ืจื—ื‘ ื‘-HCA Healthcare ื‘ืžื”ืœืš ื”ืงื™ืฅ.ย 

ื‘ื—ื’ ื”ื”ื•ื“ื™ื” ืฉืœ ืื•ืชื” ืฉื ื”, ืฉื™ืจื•ืชื™ ื”ื‘ืจื™ืื•ืช ืฉืœ ืืจื“ื ื˜ ื—ื•ื• ืžืชืงืคืช ื›ื•ืคืจ, ืžื” ืฉื’ืจื ืœืžืขืจื›ืช ื”ืžื•ื ื” 30 ื‘ืชื™ ื—ื•ืœื™ื ืœืกื’ื•ืจ ื•ืœื”ืฉืขื•ืช ื‘ืื•ืคืŸ ื™ื–ื•ื ืืช ื›ืœ ื’ื™ืฉืช ื”ืžืฉืชืžืฉื™ื ืœื™ื™ืฉื•ืžื™ ื”-IT ืฉืœื”. ื”ื“ื‘ืจ ื”ื•ื‘ื™ืœ ืœืขื™ื›ื•ื‘ื™ื ื‘ื”ืœื™ื›ื™ื ืฉืื™ื ื ื“ื—ื•ืคื™ื.ย 

ื ื›ื•ืŸ ืœืคื‘ืจื•ืืจ 2024, ื›ืชื‘ ื”ืขืช HIPAA ืชื™ืขื“ 24 ืคืจืฆื•ืช ื ืชื•ื ื™ื ืฉื›ืœืœื• 10,000 ืจืฉื•ืžื•ืช ืจืคื•ืื™ื•ืช.ย 

ืžืชืงืคื•ืช ื”ืกื™ื™ื‘ืจ ื”ืžืฉืžืขื•ืชื™ื•ืช ื‘ื™ื•ืชืจ ืฉื›ื•ื•ื ื• ื”ืฉื ื” ื ื’ื“ ืกืคืงื™ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช ื”ืชืžืงื“ื• ื‘-Change Healthcare, ื—ื‘ืจืช ื‘ืช ืฉืœ ืงื‘ื•ืฆืช UnitedHealth. ื‘ืขืงื‘ื•ืช ืžืชืงืคืช ALPHV, ื”ื—ื‘ืจื” ื”ืชืžื•ื“ื“ื” ืขื ืžืฉื‘ืจ ื›ื•ืคืจ ืฉื ื™. ื’ื•ืจืžื™ ืื™ื•ื ื˜ืขื ื• ื›ื™ ื‘ืจืฉื•ืชื 4 ื˜ืจื”-ื‘ื™ื™ื˜ ืฉืœ ื ืชื•ื ื™ ื”ื—ื‘ืจื”, ื›ื•ืœืœ ืžื™ื“ืข ืื™ืฉื™ ืžื–ื”ื” (PII) ืฉืœ ืื ืฉื™ ืฆื‘ื ืืžืจื™ืงืื™ื ืคืขื™ืœื™ื, ืจืฉื•ืžื•ืช ืจืคื•ืื™ื•ืช ืฉืœ ืžื˜ื•ืคืœื™ื, ืคืจื˜ื™ ืชืฉืœื•ื ื•ืขื•ื“.ย 

ืขืœ ืคื™ ื“ื•"ื— ืฉืœ ืื™ื’ื•ื“ ื”ื‘ืจื™ืื•ืช ื”ืืžืจื™ืงืื™, ื›ืžืขื˜ 60% ืžื‘ืชื™ ื”ื—ื•ืœื™ื ืฉื ื‘ื“ืงื• ื“ื™ื•ื•ื—ื• ืขืœ ื”ืคืกื“ื™ ื”ื›ื ืกื•ืช ื™ื•ืžื™ื™ื ืฉืœ ืœืคื—ื•ืช ืžื™ืœื™ื•ืŸ ื“ื•ืœืจ, ื›ืืฉืจ 74% ืฆื™ื™ื ื• ื›ื™ ืื™ืจื•ืข Change Healthcare ื”ืฉืคื™ืข ื™ืฉื™ืจื•ืช ืขืœ ื”ื˜ื™ืคื•ืœ ื‘ื—ื•ืœื™ื ื‘ืžืชืงื ื™ื”ื.ย 

ืชืจืฉื™ื ืขืžื•ื“ื•ืช ื”ืžืฆื™ื’ ืคืจืฆื•ืช ื ืชื•ื ื™ื ืขื™ืงืจื™ื•ืช ื™ื“ื•ืขื•ืช ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืช ืœืฉื ื™ื 2023-2024

ืจื’ื•ืœืฆื™ื” ืคื“ืจืœื™ืช ื•ืžื“ื™ื ืชื™ืช ื’ื•ื‘ืจืช

ื“ืจื™ืฉื•ืช ื—ื“ืฉื•ืช ื‘ืชืขืฉื™ื™ื” ืกื‘ื™ื‘ ืื‘ื˜ื—ืช ื ืชื•ื ื™ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช ื ืžืฆืื•ืช ื‘ืื•ืคืง, ื›ืืฉืจ ื”ืžื—ื•ืงืงื™ื ืคื•ืขืœื™ื ืœื”ื˜ื™ืœ ืื—ืจื™ื•ืช ืขืœ ืืจื’ื•ื ื™ื ืœื”ื’ื ืช ืžื™ื“ืข.ย 

HIPAA

ื›ืœืœ ื”ืคืจื˜ื™ื•ืช ืฉืœ HIPAA, 45 CFR ื—ืœืง 160 ื•ืชืชื™-ื—ืœืงื™ื A ื•-E ืฉืœ ื—ืœืง 164, ืžืชืืจื™ื ืฉื™ืžื•ืฉื™ื ื•ืžื•ืชืจื™ื ื•ื ื“ืจืฉื™ื ื•ื’ื™ืœื•ื™ ืฉืœ ืžื™ื“ืข ื‘ืจื™ืื•ืชื™ ืžื•ื’ืŸ (PHI). PHI ื™ื›ื•ืœ ืœื”ืชืงื™ื™ื ื‘ื›ืœ ืฆื•ืจื”, ื›ื•ืœืœ ืขืœ ื ื™ื™ืจ, ืกืจื˜ ื•ื‘ืฆื•ืจื” ืืœืงื˜ืจื•ื ื™ืช, ื•ื”ื•ื ื ื—ืฉื‘ ืœืžื™ื“ืข ื‘ืจื™ืื•ืชื™ ื”ืžืืคืฉืจ ื–ื™ื”ื•ื™ ื‘ืื•ืคืŸ ืื™ื ื“ื™ื‘ื™ื“ื•ืืœื™.ย 

ื›ืœืœ ื”ืื‘ื˜ื—ื” ืฉืœ HIPAA, 45 CFR ื—ืœืง 160 ื•ื—ืœืง 164, ืชืช-ื—ืœืงื™ื A ื•-C, ืžืชื•ื•ื” ืืช ื”ื“ืจื™ืฉื•ืช ืขื‘ื•ืจ PHI ืืœืงื˜ืจื•ื ื™ (ePHI). ื™ืฉื•ื™ื•ืช ืžื›ื•ืกื•ืช ื•ืฉื•ืชืคื™ื”ืŸ ื”ืขืกืงื™ื™ื ืžื—ื•ื™ื‘ื•ืช ืœืฉืžื•ืจ ืขืœ ืกื•ื“ื™ื•ืช, ืฉืœืžื•ืช ื•ื–ืžื™ื ื•ืช ืฉืœ ePHI.ย 

ื›ืœืœ ื”ื”ื•ื“ืขื” ืขืœ ื”ืคืจื•ืช HIPAA, 45 CFR ยงยง 164.400-414, ืžื—ื™ื™ื‘ ื’ื•ืคื™ื ื”ืžื›ื•ืกื™ื ื‘-HIPAA ื•ืฉื•ืชืคื™ื”ื ื”ืขืกืงื™ื™ื ืœืกืคืง ื”ื•ื“ืขื” ืœืื—ืจ ื”ืคืจื” ืฉืœ ืžื™ื“ืข ื‘ืจื™ืื•ืชื™ ืžื•ื’ืŸ ืฉืื™ื ื• ืžืื•ื‘ื˜ื—.ย 

NIST

ืคืจืกื•ื ืžื™ื•ื—ื“ 800 ืฉืœ NIST, NIST SP 800-66r2 , ืฉืคื•ืจืกื ื‘ืคื‘ืจื•ืืจ 2024, ืžืกืคืง ื”ื ื—ื™ื•ืช ืœื™ืฉื•ื™ื•ืช ืžืคื•ืงื—ื•ืช (ื›ืœื•ืžืจ, ื™ืฉื•ื™ื•ืช ื”ืžื›ื•ืกื•ืช ื‘-HIPAA ื•ืฉื•ืชืคื™ื ืขืกืงื™ื™ื) ื‘ื ื•ื’ืข ืœื”ืขืจื›ืช ื•ื ื™ื”ื•ืœ ืกื™ื›ื•ื ื™ื ืœ-ePHI, ืžื–ื”ื” ืคืขื™ืœื•ื™ื•ืช ืื•ืคื™ื™ื ื™ื•ืช ืฉื™ืฉื•ืช ืžืคื•ืงื—ืช ืขืฉื•ื™ื” ืœืฉืงื•ืœ ืœื™ื™ืฉื ื›ื—ืœืง ืžืชื•ื›ื ื™ืช ืื‘ื˜ื—ืช ืžื™ื“ืข, ื•ืžืฆื™ื’ ื”ื ื—ื™ื•ืช ืฉื™ืฉื•ื™ื•ืช ืžืคื•ืงื—ื•ืช ื™ื›ื•ืœื•ืช ืœื”ืฉืชืžืฉ ื‘ื”ืŸ, ื‘ืžืœื•ืืŸ ืื• ื‘ื—ืœืงืŸ, ื›ื“ื™ ืœืฉืคืจ ืืช ืžืฆื‘ ืื‘ื˜ื—ืช ื”ืกื™ื™ื‘ืจ ืฉืœื”ืŸ ื•ืœืกื™ื™ืข ื‘ื”ืฉื’ืช ืขืžื™ื“ื” ื‘ื›ืœืœื™ ื”ืื‘ื˜ื—ื” ืฉืœ HIPAA.ย 

HHS

ื‘ื“ืฆืžื‘ืจ 2023, ืคืจืกื ืžืฉืจื“ ื”ื‘ืจื™ืื•ืช ื•ืฉื™ืจื•ืชื™ ื”ืื ื•ืฉ (HHS) ืžืกืžืš ืงื•ื ืกืคื˜ ื”ืžืชืืจ ืืช ืืกื˜ืจื˜ื’ื™ื™ืช ืื‘ื˜ื—ืช ื”ืกื™ื™ื‘ืจ ืฉืœื• ืขื‘ื•ืจ ืžื’ื–ืจ ื”ื‘ืจื™ืื•ืช. ืืกื˜ืจื˜ื’ื™ื” ื–ื• ืžื“ื’ื™ืฉื” ืžืืžืฆื™ ืื›ื™ืคื” ืžื•ื’ื‘ืจื™ื ื•ืงื‘ื™ืขืช ืกื˜ื ื“ืจื˜ื™ื ื’ื‘ื•ื”ื™ื ื™ื•ืชืจ ืฉืœ ื ื•ื”ื’ ื‘ืชืขืฉื™ื™ื”. ืœืื—ืจ ืžื›ืŸ, ื‘ื™ื ื•ืืจ 2024, ื—ืฉืคื” HHS ืืช ื™ืขื“ื™ ื‘ื™ืฆื•ืขื™ ืื‘ื˜ื—ืช ื”ืกื™ื™ื‘ืจ (CPGs) ื”ืกืคืฆื™ืคื™ื™ื ืœืžื’ื–ืจ ื”ื‘ืจื™ืื•ืช ื•ื‘ืจื™ืื•ืช ื”ืฆื™ื‘ื•ืจ. ื™ืขื“ื™ื ืืœื” ืžื—ื•ืœืงื™ื ืœืงื˜ื’ื•ืจื™ื•ืช "ื—ื™ื•ื ื™ื•ืช" ื•"ืžืฉื•ืคืจื•ืช", ื‘ืžื˜ืจื” ืœื˜ืคืœ ื‘ืคื’ื™ืขื•ื™ื•ืช ืื‘ื˜ื—ืช ืกื™ื™ื‘ืจ ื ืคื•ืฆื•ืช ื‘ืชืขืฉื™ื™ืช ื”ื‘ืจื™ืื•ืช.ย 

ืชื•ื›ื ื™ืช HHS 405(d) ืžืฆื™ืขื” ื”ื“ืจื›ื” ืžืขืฉื™ืช ืœืืจื’ื•ื ื™ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช ื”ืžืชืžื•ื“ื“ื™ื ืขื ื”ืžื•ืจื›ื‘ื•ืช ืฉืœ ื™ื™ืฉื•ื ืืžืฆืขื™ ืื‘ื˜ื—ืช ืžื™ื“ืข ื—ื–ืงื™ื. ื™ื•ื–ืžื” ื–ื• ืžื“ื’ื™ืฉื” ืืช ื”ืฉื™ืœื•ื‘ ื”ืืกื˜ืจื˜ื’ื™ ืฉืœ ืžืขืจื›ื•ืช ืœืžื ื™ืขืช ืื•ื‘ื“ืŸ ื ืชื•ื ื™ื (DLP) ื›ืžืจื›ื™ื‘ ืžืจื›ื–ื™ ื‘ืžืกื’ืจืช ืื‘ื˜ื—ืช ื ืชื•ื ื™ื ืžืงื™ืคื”. ื”ืชืืžืช ืคืชืจื•ื ื•ืช DLP ืœืฆืจื›ื™ื ื”ื™ื™ื—ื•ื“ื™ื™ื ืฉืœ ื–ืจื™ืžื•ืช ืขื‘ื•ื“ื” ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืช ื˜ื•ืžื ืช ื‘ื—ื•ื‘ื” ืคื•ื˜ื ืฆื™ืืœ ืœื”ืคื—ื™ืช ืžืฉืžืขื•ืชื™ืช ืืช ื”ืชื•ืฆืื•ืช ื”ื—ื™ื•ื‘ื™ื•ืช ื”ืฉื’ื•ื™ื•ืช ื•ืœืฉืคืจ ืืช ื”ื™ืขื™ืœื•ืช ื”ื›ื•ืœืœืช ืฉืœ ื™ื•ื–ืžื•ืช ื”ื’ื ืช ื ืชื•ื ื™ื.ย ย 

ื”ื—ื•ืงื™ื ื”ืคื“ืจืœื™ื™ื ืฉืœ ืืจื”"ื‘

ื—ื•ืงื™ื ืคื“ืจืœื™ื™ื ื›ืžื• ื—ื•ืง Gramm-Leach-Bliley (GLBA), ื—ื•ืง ื–ื›ื•ื™ื•ืช ื”ื—ื™ื ื•ืš ื•ื”ืคืจื˜ื™ื•ืช ืฉืœ ื”ืžืฉืคื—ื” (FERPA) ื•ื—ื•ืง ื“ื™ื•ื•ื— ืืฉืจืื™ ื”ื•ื’ืŸ (FCRA) ืžื’ื ื™ื ืขืœ ืกื•ื“ื™ื•ืช ื”ืžื™ื“ืข ื”ืื™ืฉื™. ื‘ื ื•ืกืฃ ืœืชืงื ื•ืช ืคื“ืจืœื™ื•ืช ืืœื•, ื—ื•ืงื™ ืžื“ื™ื ื” ื—ื“ืฉื™ื ืžืžืฉื™ื›ื™ื ืœืฆื•ืฅ, ื”ืžื—ื–ืงื™ื ืขื•ื“ ื™ื•ืชืจ ืืช ืืžืฆืขื™ ื”ืคืจื˜ื™ื•ืช ื•ื”ื”ื’ื ื” ืขืœ ื”ืžื™ื“ืข:ย 

ืžื™ื ื•ืฃ ืžื ื™ืขืช ืื•ื‘ื“ืŸ ื ืชื•ื ื™ื ืคืจื•ืืงื˜ื™ื‘ื™ืช ื‘ืื‘ื˜ื—ืช ื ืชื•ื ื™ื ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืชย 

ื›ืืฉืจ ื ืชื•ื ื™ ื”ืžื˜ื•ืคืœื™ื ื•ื‘ื˜ื™ื—ื•ืชื ื”ื ื‘ืขืœื™ ื—ืฉื™ื‘ื•ืช ืขืœื™ื•ื ื”, ื›ื™ืฆื“ ื™ื›ื•ืœื™ื ืกืคืงื™ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช ืœื”ื™ื•ืช ื‘ื˜ื•ื—ื™ื ืฉื›ืœื™ ื”ืื‘ื˜ื—ื” ื”ืงื™ื™ืžื™ื ืฉืœื”ื ื™ืขื™ืœื™ื ื›ื ื’ื“ ืื™ื•ืžื™ื ืžืชืคืชื—ื™ื?ย 

ื—ืœื” ืขืœื™ื™ื” ื ื™ื›ืจืช ื‘ืžืชืงืคื•ืช ื”ืžื›ื•ื•ื ื•ืช ืœืกืคืงื™ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช ืื–ื•ืจื™ื™ื ืงื˜ื ื™ื ื™ื•ืชืจ, ื“ื‘ืจ ื”ืžื“ื’ื™ืฉ ืืช ื”ืฆื•ืจืš ื‘ืืžืฆืขื™ ืื‘ื˜ื—ืช ืกื™ื™ื‘ืจ ื—ื–ืงื™ื. ืืจื’ื•ื ื™ื ืืœื” ื‘ื“ืจืš ื›ืœืœ ืžืื—ืกื ื™ื ื ืชื•ื ื™ื ืจื’ื™ืฉื™ื ื‘ื™ื•ืชืจ, ืžื” ืฉื”ื•ืคืš ืื•ืชื ืœืžื˜ืจื•ืช ืขื™ืงืจื™ื•ืช ืขื‘ื•ืจ ื”ืืงืจื™ื. ื™ื™ืฉื•ื ื’ื™ืฉื•ืช ืื‘ื˜ื—ื” "ืจื‘-ืฉื›ื‘ืชื™ื•ืช", ื”ืžืฉืœื‘ื•ืช ืžื ื™ืขืช ืื•ื‘ื“ืŸ ื ืชื•ื ื™ื ื•ื–ื™ื”ื•ื™ ืื™ื•ืžื™ื ืคืจื•ืืงื˜ื™ื‘ื™, ื”ื•ื ืงืจื™ื˜ื™ ืœืžื–ืขื•ืจ ื ื–ืงื™ื ืคื•ื˜ื ืฆื™ืืœื™ื™ื.ย 

OPSWAT Proactive DLPย 

DLP ื›ื•ืœืœ ืืกื˜ืจื˜ื’ื™ื•ืช ืฉืžื˜ืจืชืŸ ืœืžื ื•ืข ื—ืฉื™ืคื” ืœื ืžื›ื•ื•ืŸ ืื• ืœื ืžื•ืจืฉื™ืช ืฉืœ ื ืชื•ื ื™ื ืจื’ื™ืฉื™ื, ื›ืžื• ืจื™ืฉื•ืžื™ ืžื˜ื•ืคืœื™ื ืื• PHI. ื–ื” ืงืจื™ื˜ื™ ื‘ืžื™ื•ื—ื“ ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืช, ืฉื ืคื’ื™ืขื” ื‘-PHI ืขืœื•ืœื” ืœื”ืฉืคื™ืข ืจื‘ื•ืช ืขืœ ืžื˜ื•ืคืœื™ื, ืžื” ืฉืขืœื•ืœ ืœื”ื•ื‘ื™ืœ ืœื’ื ื™ื‘ืช ื–ื”ื•ืช ืื• ืคื’ื™ืขื” ื‘ื˜ื™ืคื•ืœ ืจืคื•ืื™. ืงื‘ื™ืขืช ืืกื˜ืจื˜ื’ื™ื™ืช DLP ื—ื–ืงื” ื”ื™ื ื—ื™ื•ื ื™ืช ืขื‘ื•ืจ ืืจื’ื•ื ื™ื ื›ื“ื™ ืœืฆืžืฆื ืคืจืฆื•ืช ื ืชื•ื ื™ื ื•ืœืฉืžื•ืจ ืขืœ ื”ืื‘ื˜ื—ื” ื•ื”ืกื•ื“ื™ื•ืช ืฉืœ ื ืชื•ื ื™ ื”ื‘ืจื™ืื•ืช.ย 

ืึตื™ืš OPSWAT Proactive DLP ืขื‘ื•ื“ื•ืช

OPSWAT Proactive DLP ืžื–ื”ื” ื•ื—ื•ืกื ื ืชื•ื ื™ื ืจื’ื™ืฉื™ื, ื ืชื•ื ื™ื ืฉืื™ื ื ืขื•ืžื“ื™ื ื‘ืžื“ื™ื ื™ื•ืช ื•ื ืชื•ื ื™ื ืกื•ื“ื™ื™ื ื‘ืงื‘ืฆื™ื ื•ื‘ืื™ืžื™ื™ืœื™ื. ืžืฆื•ื™ื“ ื‘ืžื ื™ืขืช ืคืจืฆื•ืช ื ืชื•ื ื™ื ืคื•ื˜ื ืฆื™ืืœื™ื•ืช, Proactive DLP ืžืฉืชืžืฉ ื‘ืžื’ื•ื•ืŸ ืžืงื™ืฃ ืฉืœ ืืžืฆืขื™ ืื‘ื˜ื—ื”, ื›ื•ืœืœ ื–ื™ื”ื•ื™ ืชื•ื›ื ื•ืช ื–ื“ื•ื ื™ื•ืช ื”ืžื•ืขื‘ืจื•ืช ื‘ืงื‘ืฆื™ื, ืฉื™ืžื•ืฉ ื‘ืกื™ื•ื•ื’ ืžืกืžื›ื™ื ื”ืžื•ืคืขืœ ืขืœ ื™ื“ื™ ื‘ื™ื ื” ืžืœืื›ื•ืชื™ืช ื•ืžื™ื ื•ืฃ ื–ื™ื”ื•ื™ ืชื•ื•ื™ื ืื•ืคื˜ื™ (OCR) ืœืขืจื™ื›ืช ืžื™ื“ืข ืจื’ื™ืฉ. ื”ื•ื ืชื•ืžืš ื‘ืชืื™ืžื•ืช ืœ-HIPAA ื‘ืืžืฆืขื•ืช ืžื ื™ืขืช ืื•ื‘ื“ืŸ ื ืชื•ื ื™ื ื—ื–ืงื”, ื‘ืงืจื•ืช ื’ื™ืฉื” ื•ื™ื›ื•ืœื•ืช ื”ืคื—ืชืช ืกื™ื›ื•ื ื™ื.ย ย 

ืชืจืฉื™ื ื”ืžืžื—ื™ืฉ ื›ื™ืฆื“ OPSWAT Proactive DLP ืžืกื™ืจ ื ืชื•ื ื™ื ืจื’ื™ืฉื™ื ื›ืžื• ืคืจื˜ื™ ื›ืจื˜ื™ืก ืืฉืจืื™ ื•ืžืกืคืจื™ ื‘ื™ื˜ื•ื— ืœืื•ืžื™ ืžืงื‘ืฆื™ื ื•ื”ื•ื“ืขื•ืช ื“ื•ื"ืœ ืœืคื ื™ ื›ื ื™ืกื” ืœื–ืจื™ืžืช ืขื‘ื•ื“ื” ืžื•ืชืืžืช ืื™ืฉื™ืช

ื“ื•ื’ืžืื•ืช ืœืงื‘ืฆื™ DICOM ืฉืขื‘ืจื• ืขืจื™ื›ื”ย 

ืœืคื ื™: ืกืจื™ืงืช ืจืคื•ืื” ื’ืจืขื™ื ื™ืช ืžืงื•ืจื™ืช ื”ืžืฆื™ื’ื” ืžื™ื“ืข ืžื–ื”ื” ืฉืœ ื”ืžื˜ื•ืคืœ, ื›ื•ืœืœ ืฉื, ืชืขื•ื“ืช ื–ื”ื•ืช ื•ืชืืจื™ืš ืœื™ื“ื”

ืœืื—ืจ: ืกืจื™ืงืช ืจืคื•ืื” ื’ืจืขื™ื ื™ืช ืœืœื ื›ืœ ืžื™ื“ืข ืžื–ื”ื” ืฉืœ ื”ืžื˜ื•ืคืœ ืขืœ ืžื ืช ืœื”ื‘ื˜ื™ื— ืคืจื˜ื™ื•ืช ื•ืขืžื™ื“ื” ื‘ืชืงื ื•ืช ื”ื’ื ืช ื”ืžื™ื“ืข, ืžืขื•ื‘ื“ืช ื‘ืืžืฆืขื•ืช OPSWAT ืฉืœ Proactive DLPย 

ืœืคื ื™: ืชืžื•ื ืช ืจื ื˜ื’ืŸ ืžืงื•ืจื™ืช ื”ืžืฆื™ื’ื” ืžื™ื“ืข ืžื–ื”ื” ืฉืœ ื”ืžื˜ื•ืคืœ, ื›ื•ืœืœ ืฉื, ืชืขื•ื“ืช ื–ื”ื•ืช ื•ื›ืชื•ื‘ืช.ย 

ืœืื—ืจ: ืชืžื•ื ืช ืจื ื˜ื’ืŸ ืœืœื ื›ืœ ืคืจื˜ื™ ื”ืžื˜ื•ืคืœ ื”ืžืืคืฉืจื™ื ื–ื™ื”ื•ื™ ืขืœ ืžื ืช ืœื”ื‘ื˜ื™ื— ืคืจื˜ื™ื•ืช ื•ืขืžื™ื“ื” ื‘ืชืงื ื•ืช ื”ื’ื ืช ื”ืžื™ื“ืข, ืžืขื•ื‘ื“ืช ื‘ืืžืฆืขื•ืช OPSWAT ืฉืœ Proactive DLPย 

OPSWAT MetaDefender ืคึผืœึทื˜ืคื•ึนืจืžึธื”ย 

ืคืœื˜ืคื•ืจืžืช OPSWAT MetaDefender ืžืฆื™ืขื” ืžื ื™ืขืช ืื™ื•ืžื™ื ืžืงื™ืคื” ื”ืžื•ืชืืžืช ืœืืจื’ื•ื ื™ ืฉื™ืจื•ืชื™ ื‘ืจื™ืื•ืช ืœื˜ื™ืคื•ืœ ื‘ื ืชื•ื ื™ ื‘ืจื™ืื•ืช ื‘ืฆื•ืจื” ืžืื•ื‘ื˜ื—ืช ื•ื—ืกื›ื•ื ื™ืช. MetaDefender ื”ืคืœื˜ืคื•ืจืžื” ืžืคืฉื˜ืช ืชื”ืœื™ื›ื™ ืชืคืขื•ืœ ืื‘ื˜ื—ื”, ื ื™ืชื ืช ืœื”ืจื—ื‘ื” ื‘ืงืœื•ืช ื•ืžืกืคืงืช ื˜ื›ื ื•ืœื•ื’ื™ื•ืช ืžื•ื‘ื™ืœื•ืช ื‘ืฉื•ืง ืœืืกื˜ืจื˜ื’ื™ื™ืช ื”ื’ื ื” ืžืขืžื™ืงื”, ื›ื’ื•ืŸ:ย 

  • ื˜ื›ื ื•ืœื•ื’ื™ื™ืช Deep CDRโ„ข ืžื ื˜ืจืœืช ืงื‘ืฆื™ื ืฉืขืœื•ืœื™ื ืœื”ื™ื•ืช ื–ื“ื•ื ื™ื™ื ื•ืžื™ื™ืฆืจืช ืžื—ื“ืฉ ืชื•ื›ืŸ ื‘ื˜ื•ื— ืœืฉื™ืžื•ืฉ.
  • Multiscanning ืžื–ื”ื” ืชื•ื›ื ื•ืช ื–ื“ื•ื ื™ื•ืช ื™ื“ื•ืขื•ืช ื•ืœื ื™ื“ื•ืขื•ืช ืขื ื™ื•ืชืจ ืž-30 ืžื ื•ืขื™ ืื ื˜ื™-ื•ื™ืจื•ืก.
  • Sandbox Adaptive ืžื–ื”ื” ืชื•ื›ื ื•ืช ื–ื“ื•ื ื™ื•ืช ื‘ืืžืฆืขื•ืช ื ื™ืชื•ื— ื“ื™ื ืžื™ ื•ืกื˜ื˜ื™.
  • ืžื“ื™ื ืช ื”ืžื•ืฆื ืžื’ื‘ื™ืœื” ืืช ื”ื’ื™ืฉื” ืœื ืชื•ื ื™ื ืขืœ ืกืžืš ืžื™ืงื•ื ื•ืกืคืง.
ืชืจืฉื™ื ืฉืœ OPSWAT ืฉืœ MetaDefender ืคืœื˜ืคื•ืจืžื” ืœืื‘ื˜ื—ืช ืกื™ื™ื‘ืจ ืžืงืฆื” ืœืงืฆื”

ื’ืœื” ื›ื™ืฆื“ OPSWAT MetaDefender ืคืœื˜ืคื•ืจืžื” ื™ื›ื•ืœื” ืœืกื™ื™ืข ืœื’ื•ืคื™ ื‘ืจื™ืื•ืช ื‘ืืชื’ืจื™ ืื‘ื˜ื—ืช ื”ืžื™ื“ืข ืฉืœื”ื ื‘ืžืกืžืš ื–ื”.

ืžื™ืคื•ื™ ืขืชื™ื“ ืื‘ื˜ื—ืช ืฉื™ืจื•ืชื™ ื”ื‘ืจื™ืื•ืช ื”ื“ื™ื’ื™ื˜ืœื™ื™ืย 

ืžื’ื–ืจ ื”ื‘ืจื™ืื•ืช ื ื™ืฆื‘ ื‘ืคื ื™ ืื™ื•ื ืžืชืžืฉืš ืžืฆื“ ืžืชืงืคื•ืช ืกื™ื™ื‘ืจ ืžืชื•ื—ื›ืžื•ืช ื™ื•ืชืจ ื•ื™ื•ืชืจ, ื›ื•ืœืœ ืžืชืงืคื•ืช ื”ืžื•ื ืขื•ืช ืขืœ ื™ื“ื™ ื‘ื™ื ื” ืžืœืื›ื•ืชื™ืช, ื”ืžืฆื™ื‘ื•ืช ืืชื’ืจ ืื“ื™ืจ ื”ืขื•ืœื” ืขืœ ืืžืฆืขื™ ืื‘ื˜ื—ื” ืงื•ื ื‘ื ืฆื™ื•ื ืœื™ื™ื. ืชื•ื›ื ื™ื•ืช ืคื™ืฉื™ื ื’ ืžื•ืชืืžื•ืช ืื™ืฉื™ืช, ื ื™ืฆื•ืœ ืื•ื˜ื•ืžื˜ื™ ืฉืœ ืคื’ื™ืขื•ื™ื•ืช ื‘ืžืขืจื›ื•ืช ื•ื’ื•ืจืžื™ ืกื™ื›ื•ืŸ ื”ื•ืœื›ื™ื ื•ื’ื“ืœื™ื ืื—ืจื™ื ื”ื ื’ืจืžื™ื ื›ืชื•ืฆืื” ืžื“ื™ื’ื™ื˜ืฆื™ื” ื•ืื•ื˜ื•ืžืฆื™ื” ืžื•ื’ื‘ืจื•ืช ืžื”ื•ื•ื™ื ืกื™ื›ื•ืŸ ื—ืžื•ืจ ืœืฉืœืžื•ืช ื ืชื•ื ื™ ื”ืžื˜ื•ืคืœื™ื ื•ืœื”ืžืฉื›ื™ื•ืช ื”ืชืคืขื•ืœื™ืช.ย ย 

ื›ื“ื™ ืœื”ื™ืœื—ื ื‘ื™ืขื™ืœื•ืช ื‘ืื™ื•ืžื™ื ื”ืžืชืคืชื—ื™ื ื”ืœืœื•, ืฆื•ื•ืชื™ IT ื‘ืชื—ื•ื ื”ื‘ืจื™ืื•ืช ื—ื™ื™ื‘ื™ื ืœื™ื™ืฉื ืคืจื•ื˜ื•ืงื•ืœื™ ื”ื’ื ืช ื ืชื•ื ื™ื ื—ื–ืงื™ื ื›ื“ื™ ืœื”ื’ืŸ ืขืœ ืžื™ื“ืข ืจืคื•ืื™ ืจื’ื™ืฉ ืžืคื ื™ ื’ื•ืจืžื™ ืื™ื•ื. ื’ื™ืฉื” ืคืจื•ืืงื˜ื™ื‘ื™ืช ื–ื• ืžื‘ื˜ื™ื—ื” ืฉืืจื’ื•ื ื™ ืฉื™ืจื•ืชื™ ื”ื‘ืจื™ืื•ืช ื™ื”ื™ื• ืžืฆื•ื™ื“ื™ื ื”ื™ื˜ื‘ ืœืขืžื•ื“ ื‘ืชืงื ื™ ืชืื™ืžื•ืช ื•ืœื”ืžืฉื™ืš ืœืกืคืง ื˜ื™ืคื•ืœ ืงืจื™ื˜ื™ ืœืžื˜ื•ืคืœื™ื”ื.ย 

Secure ื”ื ืชื•ื ื™ื ื”ืจื’ื™ืฉื™ื ืฉืœ ื”ืืจื’ื•ืŸ ืฉืœืš ื”ื™ื•ื.ย ย 

ื”ื™ืฉืืจ ืžืขื•ื“ื›ืŸ ืขื OPSWAT !

ื”ื™ืจืฉืžื• ืขื•ื“ ื”ื™ื•ื ื›ื“ื™ ืœืงื‘ืœ ืืช ื”ืขื“ื›ื•ื ื™ื ื”ืื—ืจื•ื ื™ื ืฉืœ ื”ื—ื‘ืจื”, ืกื™ืคื•ืจื™ื, ืžื™ื“ืข ืขืœ ืื™ืจื•ืขื™ื ื•ืขื•ื“.